Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05652335 · ClinicalTrials.gov registry record · Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

A Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis, sponsored by Janssen Research & Development.

Recruiting
Registry status
Phase 1
Development phase
180
Enrollment target
20
Study locations

NCT05652335: Recruiting Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis, sponsored by Janssen Research & Development.

NCT05652335 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 180 participants, below the 324-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05652335, a Phase 1 study of Relapsed or Refractory Multiple Myeloma and Previously Treated Amyloid Light-chain (AL) Amyloidosis, is actively recruiting participants, sponsored by Janssen Research & Development.

RECRUITING
Registry status
Phase 1
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).

Primary Outcome

DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Conditions Studied

Relapsed or Refractory Multiple Myeloma Previously Treated Amyloid Light-chain (AL) Amyloidosis

Interventions

  • DRUG JNJ-79635322

Study Locations (20)

Other

  • UZ Antwerpen - Edegem
  • UZ Gent - Ghent
  • CHU de Liege - Liège
  • CHU Nantes - Nantes
  • CHU Lyon Sud - Pierre-Bénite
  • Chu Rennes Hopital Pontchaillou - Rennes
  • Institut Claudius Regaud - Toulouse
  • Japanese Red Cross Medical Center - Shibuya City
  • Osaka University Hospital - Suita-shi
  • The Cancer Institute Hospital of JFCR - Tokyo
  • VUMC Amsterdam - Amsterdam

California

  • City of Hope - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • University of California San Francisco - San Francisco

New York

  • Icahn School of Medicine at Mt. Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • Colorado Blood Cancer Institute - Denver

North Carolina

  • Levine Cancer Institute - Charlotte

Pennsylvania

  • University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2022-11-22
Est. Completion 2028-08-07
Phase Phase 1
Janssen Research & Development

593 total trials

What NCT05652335 shows while recruiting

NCT05652335 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 324-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (44% lower).

The record links to 2 conditions, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which JNJ-79635322 is the first listed.

NCT05652335 names 20 study sites across 7 states, led by Other, California, New York.

Frequently Asked Questions

What is clinical trial NCT05652335 about?

NCT05652335 is a clinical study titled "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis". The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansio...

What is the current status of trial NCT05652335?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-11-22. Estimated completion is 2028-08-07.

What conditions does trial NCT05652335 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis.

What interventions are being tested in trial NCT05652335?

The interventions under investigation include: JNJ-79635322 (DRUG).

Who is sponsoring clinical trial NCT05652335?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05652335 being conducted?

This trial has 20 study locations across California, Colorado, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05652335's enrollment target sits among peer trials

180 5th of 10 higher than 6 of 10 other Relapsed or Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05652335

Source: ClinicalTrials.gov NCT05652335, the US trial registry maintained by the National Library of Medicine. NCT05652335 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.